Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07829029
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Nocturia
  • Nocturnal Urinary Incontinence

Eligibility Criteria

Sex
FEMALE
Age
60 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • TolterodineTartrate ER — DRUG
    Anticholinergic
  • Mirabegron — DRUG
    Beta-3-adrenergic agonist
  • Placebo — DRUG
    matching placebo pill

Study Details

The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed tocompare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonistbladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinaryincontinence and either normal or mildly impaired cognitive function at baseline.

Key Dates

First listed
Sep 18, 2026
Start date
Oct 4, 2022
Status verified
Sep 2026
Primary completion
May 2, 2027
Completion
May 2, 2027

Study Design

Enrollment
270 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Anticholinergic bladder medication plusbehavioral self-management education
    Tolterodine tartrate is a muscarinic receptor antagonist designed to treat urgency incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urge suppression
  • Active Comparator: Beta-3-adrenergic agonist medication plusbehavioral self-management education
    Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
  • Placebo Comparator: Placebo medication plus behavioral self-management education
    Microcrystalline cellulose placebo encapsulated to appear identical to tolterodine and mirabegron medication will be prepared by a compounding pharmacy. Behavioral self-management education includes written education about time duration, lifestyle changes, pelvic floor muscle exercises, and urge suppression.

Primary Outcome Measure

Change in nocturnal urination frequency over 6 months (24 weeks) of treatment, based on a validated voiding diary. [ Time Frame: Baseline to 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94115
Claudia Vila Manes
[email protected]
415-885-7547
Amy Zhang
[email protected]
(415) 885-7547
Alison Huang, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CA

Related Studies